# A Study of Teriparatide in Japanese Osteoporosis Patients

> **NCT01430104** · PHASE4 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 30 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Teriparatide
- **DRUG:** Aspara-CA 600 mg
- **DRUG:** Alfarol 1.0 µg

## Key facts

- **NCT ID:** NCT01430104
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2013-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01430104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01430104, "A Study of Teriparatide in Japanese Osteoporosis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01430104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*